| |
| |
|
| Insider
Information: |
Schmid John P. |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
69,974 |
|
|
Indirect Shares
|
26,965 |
|
|
| Direct
Value |
$83,709 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
96,939 |
|
|
| Total
Value |
$83,709 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Trius Therapeutics Inc |
TSRX |
Chief Financial Officer |
2013-09-11 |
0 |
|
0 |
Premium* |
|
|
Auspex Pharmaceuticals, Inc. |
ASPX |
Chief Financial Officer |
2015-05-05 |
0 |
|
0 |
Premium* |
|
|
Neos Therapeutics, Inc. |
NEOS |
Director |
2021-03-19 |
0 |
2020-06-10 |
0 |
Premium* |
|
|
Design Therapeutics, Inc. |
DSGN |
|
2024-03-25 |
30,674 |
2024-03-25 |
26,965 |
Premium* |
|
|
Xeris Pharmaceuticals Inc |
XERS |
Director |
2021-10-05 |
0 |
2021-10-05 |
0 |
Premium* |
|
|
Poseida Therapeutics, Inc. |
PSTX |
|
2023-06-15 |
39,300 |
2022-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| DSGN |
Design Therapeutics, Inc. |
|
– • – |
2024-03-25 |
4 |
B |
$3.74 |
$66,606 |
I/I |
17,809 |
26,965 |
0.01 |
- |
|
| DSGN |
Design Therapeutics, Inc. |
|
– • – |
2024-03-22 |
4 |
B |
$3.62 |
$33,133 |
I/I |
9,156 |
9,156 |
0.01 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
|
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
39,300 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,650 |
19,650 |
0 |
- |
|
| XERS |
Xeris Pharmaceuticals Inc |
Director |
– • – |
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,659) |
0 |
0 |
- |
|
| DSGN |
Design Therapeutics, Inc. |
Director |
– • – |
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,674 |
|
- |
|
| NEOS |
Neos Therapeutics, Inc. |
Director |
– • – |
2021-03-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(23,453) |
0 |
0 |
- |
|
| NEOS |
Neos Therapeutics, Inc. |
Director |
– • – |
2020-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
23,453 |
23,453 |
0 |
- |
|
| ASPX |
Auspex Pharmaceuticals, I... |
Chief Financial Officer |
• – – |
2015-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(144,444) |
0 |
0 |
- |
|
| ASPX |
Auspex Pharmaceuticals, I... |
Chief Financial OfficerOfficer |
• – – |
2014-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
144,444 |
|
- |
|
| TSRX |
Trius Therapeutics Inc |
Chief Financial Officer |
• – – |
2013-09-11 |
4 |
D |
$0.00 |
$0 |
D/D |
(107,639) |
0 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2012-06-22 |
4 |
AS |
$6.00 |
$10,800 |
D/D |
(1,800) |
107,639 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2012-03-27 |
4 |
OE |
$1.29 |
$6,450 |
D/D |
5,000 |
109,439 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2012-03-01 |
4 |
AS |
$5.04 |
$2,520 |
D/D |
(500) |
104,439 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2012-02-02 |
4 |
AS |
$5.63 |
$2,815 |
D/D |
(500) |
104,939 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2012-01-03 |
4 |
AS |
$7.28 |
$5,096 |
D/D |
(700) |
105,439 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-12-01 |
4 |
AS |
$7.50 |
$5,250 |
D/D |
(700) |
106,139 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-11-07 |
4 |
AS |
$7.00 |
$700 |
D/D |
(100) |
106,839 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-10-26 |
4 |
AS |
$7.00 |
$1,400 |
D/D |
(200) |
107,539 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-10-03 |
4 |
AS |
$6.33 |
$3,798 |
D/D |
(600) |
107,739 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-09-01 |
4 |
AS |
$6.60 |
$3,960 |
D/D |
(600) |
108,339 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-08-01 |
4 |
AS |
$8.78 |
$10,622 |
D/D |
(1,200) |
108,939 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-07-20 |
4 |
AS |
$8.00 |
$800 |
D/D |
(100) |
110,139 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-07-01 |
4 |
AS |
$7.93 |
$5,550 |
D/D |
(700) |
110,239 |
0 |
- |
|
| TSRX |
Trius Therapeutics Inc |
CFO and Secretary |
• – – |
2011-06-01 |
4 |
AS |
$7.89 |
$6,323 |
D/D |
(800) |
110,939 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
